載入...
Impact of enzalutamide on patient-related outcomes in metastatic castration-resistant prostate cancer: current perspectives
Prostate cancer claims the lives of more than 25,000 men in the United States yearly, most from metastatic disease. In the past decade, several new medications have been approved for the treatment of metastatic prostate cancer including the antiandrogen enzalutamide. In addition, there has been moun...
Na minha lista:
| 發表在: | Res Rep Urol |
|---|---|
| Main Authors: | , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
Dove Medical Press
2016
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5136356/ https://ncbi.nlm.nih.gov/pubmed/27942507 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/RRU.S104789 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|